FindTrial
Sign In

To study the expression of HER2 immunohistochemistry in gastric cancer

The expression of HER2 low in gastric and gastroesophageal junction adenocarcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070266
Enrollment
60
Registered
2024-07-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K318- Other specified diseases of stomach and duodenum

Interventions

Intervention1: NIL: NIL

Sponsors

G B Pant institute of post graduate medical education and research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Histopathological diagnosis of gastric or gastroesophageal junction adenocarcinoma

Exclusion criteria

Exclusion criteria: Patients on neoadjuvant therapy, recurrent gastric/gastroesophageal junction adenocarcinoma and inadequate biopsy material.

Design outcomes

Primary

MeasureTime frame
Percentage of cases showing expression of HER2 low expression in Gastric and Gastroesophageal adenocarcinoma.Timepoint: Baseline—

Secondary

MeasureTime frame
1.Association of HER2 low expression with clinical parameters i.e age, sex & duration of symptoms. 2.Association of HER2 low expression with histopathological features i.e tumor grade, tumor stage, histological subtype, H. pylori status.Timepoint: Baseline—

Countries

India

Contacts

Public ContactDr Puja Sakhuja

G B Pant institute of post graduate medical education and research

pujasak@gmail.com9718599073

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026